Press statement: EACI: Dupixent showed a superiority over Xolair (omalizumab) in chronic rhinitis with the nasal benign tumors in patients who suffer from asthma in the fourth stage that was previously presented to-
[og_img]
Source link
Press statement: EACI: Dupixent showed a superiority over Xolair (omalizumab) in chronic rhinitis with the nasal benign tumors in patients who suffer from asthma in the fourth stage that was previously presented to-
[og_img]
Source link